We're just getting started. Our biggest achievements are still ahead of us and we won't stop until we find a cure. Our goals and strategies to get us there include:
Awarding $1.5 million of grant funding in 2023
Harnessing the potential of our community through our simple and easy-to-use community events fundraising platform
Establishing fresh merchandise partnerships
Collaborating with the brightest minds in nonprofit strategy
Working to provide a platform to accelerate ambitious ALS researchers with nontraditional approaches
Grants We’ve Awarded
Sean M. Healey and AMG Center for ALS
In December 2022, we proudly awarded a $100,000 grant to The Sean M. Healey and AMG Center for ALS. This grant will support their tireless work to discover new ways to diagnose and treat this disease.
Our second $100,000 grant went to support the ambitious researchers at Duke University. We were impressed with their approach and granted them significant funding to support their Replication Of ALS Reversals, or “ROAR” trials. These researchers also used the Deep Integrated Genomic Analysis Platform to test treatments against 4 different subclassifications of ALS.
Their work is ongoing, and we look forward to learning more from them at the conclusion of their study.
ALS Therapy Development Institute
In August 2023, with our 3rd grant, we awarded $100,000 to support the ALS Therapy Development Institute (ALS TDI) and its mission to end ALS. To help achieve this mission, ALS TDI is collectively building the world’s largest ALS data base, allowing them to connect the dots for a cure.
Our grant was directed to aid in the expansion of the ALS Research Collaborative (ARC), a global initiative that partners with ALS patients around the world to gather data about their disease and then shares this data with researchers across the globe through a cloud-based data sharing platform.
Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital
In September 2023, we awarded our largest grant to date with a $225,000 donation to the Vaccine and Immunotherapy Center at Massachusetts General Hospital.
This grant will directly support an inventive and ambitious B-Cell study by the researchers at the VIC in collaboration with additional researchers from the Healey Center for ALS. The study aims to further test earlier indications that B-cells could be used to effectively slow, reverse, and or prevent development of ALS.
Innovative biotechnology firm specializing in mitochondrial therapies
In January, 2024 we invested in MitoSense, an innovative biotechnology firm specializing in mitochondrial therapies. This collaboration marks a significant step in advancing MitoSense's flagship technology, MOT™ (Mitochondria Organelle Transplantation), a promising new approach to ALS treatment.
MOT™, a novel therapeutic concept developed by MitoSense, leverages the unique capabilities of mitochondria to combat the progression of ALS. By directly transplanting healthy mitochondria into affected cells, MOT™ seeks to restore cellular function and slow down, or potentially reverse, the debilitating symptoms of ALS. This approach represents a groundbreaking shift in the battle against this relentless disease, offering hope where traditional treatments have seen limited success.
We look forward to the many milestones Hop On A Cure will achieve in the future and to educating the world on the impact of ALS. Most of all, we look forward to relentlessly doing our part to help the world kick ALS’ ass.